moneyheap
MDLN · Analysis updated Nov 5, 2026, 4:26 AM ET
Why is Medline Inc. (MDLN) stock moving?
Medline delivered strong third-quarter results on Nov 4, with revenue climbing 10.4% year-over-year to $7.9B and adjusted diluted EPS reaching $0.44, surpassing Wall Street expectations of $7.71B and $0.35, respectively. Operational strength was spearheaded by its Supply Chain Solutions unit, which expanded 14% to $4.2B amid new customer acquisitions. In response to steady customer demand, management raised full-year 2026 organic sales guidance to 10.0%-10.5% and reaffirmed adjusted EBITDA targets of $3.3B-$3.4B. Capital allocation initiatives also provided a major boost to sentiment, as the board authorized a new $1B share repurchase program alongside a $750M principal prepayment on its term loan facility, driving a sharp post-earnings rally of more than 15%.
News behind the analysis
- Medline Reports Third Quarter and Nine Months 2026 ResultsMedline reported Q3 net sales of $7.9B, up 10.4%, with adjusted diluted EPS of $0.44 and adjusted EBITDA of $960M, beating consensus estimates.
- Medline Q3 2026 Slides: Sales Rise 10%, Shares Jump on Guidance and $1B BuybackMedline shares jumped over 15% after raising full-year organic sales growth guidance to 10.0%-10.5% and authorizing a $1B share repurchase program.
- Medline (MDLN) Exceeds Wall Street Expectations with Double-Digit Sales Growth in Q3Growth was driven by the Supply Chain Solutions segment delivering $4.2B in sales, up 14% year-over-year from new customer signings and volume expansion.
- Medline (MDLN) Shares Surge After Q3 Earnings Beat and $1B Buyback AnnouncementMedline stock surged past $39 after beating Q3 consensus EPS by $0.09 and revenue estimates by $180M, alongside a $750M debt prepayment.
- Medline CEO Jim Boyle Scheduled to Present at Jefferies Global Healthcare ConferenceMedline announced that CEO Jim Boyle will present at the Jefferies Global Healthcare Conference in London on November 17, 2026.